Molecular mechanisms of acquired resistance to EGFR-TKIs have been well elucidated, including secondary T790M mutation (50–60%), MET amplification (5–22%), HER2 amplification (~ 12%) and transformation to small cell lung cancer (SCLC) (3–10%) [4–8]. Here, ERBB2 is linked to small cell lung carcinoma.